Racemorphan: Difference between revisions

Racemorphan
Legal status
Legal status	AU: S9 (Prohibited substance); BR: Class A1 (Narcotic drugs); CA: Schedule I; DE: Anlage II (Authorized trade only, not prescriptible); UK: Class A; US: Schedule II; UN: Psychotropic Schedule I;
Identifiers
	IUPAC name (±)-17-Methylmorphinan-3-ol;
CAS Number	297-90-5 ; 5985-35-3 (HBr);
PubChem CID	3918;
ChemSpider	3781;
UNII	V7R79HN3XD;
ChEMBL	ChEMBL20803;
ECHA InfoCard	100.005.499
Chemical and physical data
Formula	C17H23NO
Molar mass	257.377 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CN1CCC23CCCCC2C1Cc4ccc(O)cc34;
	InChI InChI=1S/C17H23NO/c1-18-9-8-17-7-3-2-4-14(17)16(18)10-12-5-6-13(19)11-15(12)17/h5-6,11,14,16,19H,2-4,7-10H2,1H3; Key:JAQUASYNZVUNQP-UHFFFAOYSA-N;

Browse history interactively

← Previous edit

Content deleted Content added

VisualWikitext

Inline

Latest revision as of 00:30, 26 March 2024

Racemorphan, or morphanol, is the racemic mixture of the two stereoisomers of 17-methylmorphinan-3-ol, each with differing pharmacology and effects:

Dextrorphan – an antitussive and dissociative hallucinogen (NMDA receptor antagonist)
Levorphanol – an opioid analgesic

Racemorphan itself is under international control per the Single Convention on Narcotic Drugs 1961 and is therefore listed as a Schedule II Narcotic controlled substance in the US Controlled Substances Act 1970; it has an ACSCN of 9733 and in 2014 it had an aggregate annual manufacturing quota of zero. ^[2] The salts in use are hydrobromide (free base conversion ratio 0.741), hydrochloride (0.876), and tartrate (0.632).

References

^ Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.
^ "Conversion Factors for Controlled Substances". www.deadiversion.usdoj.gov.

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

This drug article relating to the respiratory system is a stub. You can help Wikipedia by expanding it.

[1] Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.

[2] "Conversion Factors for Controlled Substances". www.deadiversion.usdoj.gov.

[1]

[2]

@@ Line 46: / Line 46: @@
 '''Racemorphan''', or '''morphanol''', is the [[racemic mixture]] of the two [[stereoisomer]]s of 17-methylmorphinan-3-ol, each with differing [[pharmacology]] and [[therapeutic effect|effect]]s:
-* [[Dextrorphan]] - an [[antitussive]] and  [[dissociative drug|dissociative]] [[hallucinogen]] ([[NMDA receptor antagonist]])
+* [[Dextrorphan]]{{snd}} an [[antitussive]] and  [[dissociative drug|dissociative]] [[hallucinogen]] ([[NMDA receptor antagonist]])
-* [[Levorphanol]] - an [[opioid]] [[analgesic]]
+* [[Levorphanol]]{{snd}} an [[opioid]] [[analgesic]]
 Racemorphan itself is under international control per the Single Convention on Narcotic Drugs 1961 and is therefore listed as a Schedule II Narcotic controlled substance in the US Controlled Substances Act 1970; it has an ACSCN of 9733 and in 2014 it had an aggregate annual manufacturing quota of zero. <ref>{{cite web|url=http://www.deadiversion.usdoj.gov/quotas/conv_factor/index.html|title=Conversion Factors for Controlled Substances|website=www.deadiversion.usdoj.gov}}</ref>  The salts in use are hydrobromide (free base conversion ratio  0.741), hydrochloride (0.876), and tartrate (0.632).

Racemorphan: Difference between revisions

Latest revision as of 00:30, 26 March 2024

See also

See also

References